Meropenem microbiology: Difference between revisions
(Created page with "==Microbiology== Meropenem is a broad-spectrum Carbapenem antibiotic. It is active against Gram-positive and Gram- negative bacteria. The bactericidal activity of me...") |
|||
| Line 1: | Line 1: | ||
==Microbiology== | ==Microbiology== | ||
Meropenem is a broad-spectrum [[Carbapenem]] antibiotic. It is active against Gram-positive and Gram- | Meropenem is a broad-spectrum [[Carbapenem]] antibiotic. It is active against Gram-positive and Gram-negative bacteria. The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding-protein (PBP) targets. Its strongest affinities are toward PBPs 2, 3 and 4 of [[Escherichia coli]] and [[Pseudomonas | ||
negative bacteria. | aeruginosa]]; and PBPs 1, 2 and 4 of [[Staphylococcus aureus]]. Bactericidal concentrations (defined as a 3 log10 reduction in cell counts within 12 to 24 hours) are typically 1-2 times the bacteriostatic concentrations of meropenem, with the exception of [[Listeria monocytogenes]] | ||
The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem | |||
readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin- | |||
binding-protein (PBP) targets. Its strongest affinities are toward PBPs 2, 3 and 4 of [[Escherichia coli]] | |||
and [[Pseudomonas aeruginosa]]; and PBPs 1, 2 and 4 of [[Staphylococcus aureus]]. Bactericidal | |||
concentrations (defined as a 3 log10 reduction in cell counts within 12 to 24 hours) are typically 1-2 | |||
times the bacteriostatic concentrations of meropenem, with the exception of [[Listeria monocytogenes]] | |||
against which lethal activity is not observed. | against which lethal activity is not observed. | ||
Meropenem has significant stability to hydrolysis by β-lactamases of most categories, both penicillinases and cephalosporinases produced by Gram-positive and Gram-negative bacteria. | |||
Meropenem has significant stability to hydrolysis by β-lactamases of most categories, both | Meropenem should not be used to treat methicillin-resistant [[staphylococci]] (MRSA). | ||
penicillinases and cephalosporinases produced by Gram-positive and Gram-negative bacteria. | |||
Meropenem should not be used to treat methicillin-resistant [[staphylococci]] (MRSA). | |||
In vitro tests show meropenem to act synergistically with aminoglycoside antibiotics against some | In vitro tests show meropenem to act synergistically with aminoglycoside antibiotics against some | ||
isolates of [[Pseudomonas aeruginosa]]. | isolates of [[Pseudomonas aeruginosa]]. | ||
Revision as of 20:40, 19 December 2013
Microbiology
Meropenem is a broad-spectrum Carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding-protein (PBP) targets. Its strongest affinities are toward PBPs 2, 3 and 4 of Escherichia coli and [[Pseudomonas aeruginosa]]; and PBPs 1, 2 and 4 of Staphylococcus aureus. Bactericidal concentrations (defined as a 3 log10 reduction in cell counts within 12 to 24 hours) are typically 1-2 times the bacteriostatic concentrations of meropenem, with the exception of Listeria monocytogenes against which lethal activity is not observed. Meropenem has significant stability to hydrolysis by β-lactamases of most categories, both penicillinases and cephalosporinases produced by Gram-positive and Gram-negative bacteria. Meropenem should not be used to treat methicillin-resistant staphylococci (MRSA). In vitro tests show meropenem to act synergistically with aminoglycoside antibiotics against some isolates of Pseudomonas aeruginosa.